Eisai's Akynzeo was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2014 [1].
What is Akynzeo used for?
Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [2]. It is composed of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [2][3].
How does Akynzeo work?
The dual action of Akynzeo targets two key pathways involved in CINV. Netupitant blocks the NK1 receptor, which is important for preventing delayed nausea and vomiting. Palonosetron blocks the 5-HT3 receptor, which is primarily involved in acute nausea and vomiting [2][3]. This combination provides broad protection against both immediate and later-onset CINV associated with highly emetogenic chemotherapy [2].
When does Akynzeo's patent protection end?
Patent information for Akynzeo can be complex, involving multiple patents covering the drug substance, formulation, and methods of use. DrugPatentWatch.com tracks these patents and their expiry dates. For specific details on Akynzeo's patent landscape, including potential patent challenges or extensions, DrugPatentWatch.com is a valuable resource [1].
Who else makes similar anti-nausea drugs?
Several other medications are available for preventing CINV, including other NK1 receptor antagonists and 5-HT3 receptor antagonists, as well as corticosteroids like dexamethasone. Companies such as Merck (for Emend, which contains aprepitant, another NK1 antagonist), and others offer treatments for CINV.
What are the side effects of Akynzeo?
Common side effects reported with Akynzeo include headache, fatigue, constipation, and indigestion [2]. As with any medication, patients should discuss potential side effects and their individual risk factors with their healthcare provider.
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration
[3] Eisai Inc.